Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $185
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Natera (NTRA) and Regeneron (REGN)
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $200 to $251
Natera Inc. Shines in Earnings Call With Strong Growth
Express News | UBS Maintains Buy on Natera, Raises Price Target to $218
